112 related articles for article (PubMed ID: 21591994)
1. Amonafide: a potential role in treating acute myeloid leukemia.
Allen SL; Lundberg AS
Expert Opin Investig Drugs; 2011 Jul; 20(7):995-1003. PubMed ID: 21591994
[TBL] [Abstract][Full Text] [Related]
2. Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux.
Chau M; Christensen JL; Ajami AM; Capizzi RL
Leuk Res; 2008 Mar; 32(3):465-73. PubMed ID: 17826829
[TBL] [Abstract][Full Text] [Related]
3. Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?
Freeman CL; Swords R; Giles FJ
Expert Rev Hematol; 2012 Feb; 5(1):17-26. PubMed ID: 22272701
[TBL] [Abstract][Full Text] [Related]
4. Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia.
Allen SL; Kolitz JE; Lundberg AS; Bennett JM; Capizzi RL; Budman DR
Leuk Res; 2010 Apr; 34(4):487-91. PubMed ID: 19748672
[TBL] [Abstract][Full Text] [Related]
5. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
Stone RM; Mazzola E; Neuberg D; Allen SL; Pigneux A; Stuart RK; Wetzler M; Rizzieri D; Erba HP; Damon L; Jang JH; Tallman MS; Warzocha K; Masszi T; Sekeres MA; Egyed M; Horst HA; Selleslag D; Solomon SR; Venugopal P; Lundberg AS; Powell B
J Clin Oncol; 2015 Apr; 33(11):1252-7. PubMed ID: 25732165
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Willman CL
Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
[TBL] [Abstract][Full Text] [Related]
7. R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II.
Zhu H; Huang M; Yang F; Chen Y; Miao ZH; Qian XH; Xu YF; Qin YX; Luo HB; Shen X; Geng MY; Cai YJ; Ding J
Mol Cancer Ther; 2007 Feb; 6(2):484-95. PubMed ID: 17308047
[TBL] [Abstract][Full Text] [Related]
8. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
Valkov NI; Sullivan DM
Semin Hematol; 1997 Oct; 34(4 Suppl 5):48-62. PubMed ID: 9408961
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs.
Hsiang YH; Jiang JB; Liu LF
Mol Pharmacol; 1989 Sep; 36(3):371-6. PubMed ID: 2550774
[TBL] [Abstract][Full Text] [Related]
12. Etoposide-induced DNA strand breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL.
Zhou R; Vitols S; Gruber A; Liliemark J; Wang Y; Liliemark E
Br J Haematol; 1999 May; 105(2):420-7. PubMed ID: 10233413
[TBL] [Abstract][Full Text] [Related]
13. Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?
Freeman C; Keane N; Swords R; Giles F
Expert Opin Pharmacother; 2013 Jul; 14(10):1417-27. PubMed ID: 23688047
[TBL] [Abstract][Full Text] [Related]
14. Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.
Tran H; Yang D
Ann Pharmacother; 2012 Jan; 46(1):89-96. PubMed ID: 22170975
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
Kantarjian HM; Erba HP; Claxton D; Arellano M; Lyons RM; Kovascovics T; Gabrilove J; Craig M; Douer D; Maris M; Petersdorf S; Shami PJ; Yeager AM; Eckert S; Abichandani R; Faderl S
J Clin Oncol; 2010 Feb; 28(4):549-55. PubMed ID: 20026805
[TBL] [Abstract][Full Text] [Related]
17. Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
Feldman EJ
Best Pract Res Clin Haematol; 2011 Dec; 24(4):523-6. PubMed ID: 22127315
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
20. Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia.
Roboz GJ
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S22-4. PubMed ID: 18760707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
